UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000016138 |
|---|---|
| Receipt number | R000018738 |
| Scientific Title | A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours |
| Date of disclosure of the study information | 2015/01/07 |
| Last modified on | 2019/02/25 13:00:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Acronym
Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Scientific Title
A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Scientific Title:Acronym
Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Region
| Japan | Europe |
Condition
Condition
Ovarian Sex-cord Stromal Tumor
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To evaluate clinical benefit of combining bevacizumab treatment to weekly paclitaxel.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
To evaluate the clinical benefit of combining bevacizumab treatment to weekly paclitaxel measured by the non-progression rate after 6 months of treatment.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Paclitaxel
Interventions/Control_2
Bevacizumab
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
1.Female aged >=18 years at inclusion
2.Histologically confirmed diagnosis of ovarian Sex cord-stromal tumors including the following cell types: granulosa cell tumours (adults and juveniles types), granulosa cell-theca cell tumour, Sertoli-Leydig cell tumours, malignant steroid cell tumours, gynandroblastoma, unclassified SCST and mixed tumours
3.Documented relapse of SCST defined by progression of disease (radiologic, clinic or biological progression)
4.At least one measurable site of disease as defined by RECIST 1.1
5.Patients must have been pre-treated with at least 1 prior line of platinum-based chemotherapy
6.Adequate bone marrow, liver and renal functions including the following:
1)Absolute neutrophil count >=1.5 G/L, platelet count >=100 G/L, and hemoglobin >= 9 g/dL. Prior transfusion is authorized to keep haemoglobin level to >= 9 g/dL
2)AST/ALT <= 3 x upper limit of normal (ULN) (or <= 5.0 ULN if liver metastasis) and total bilirubin <= 1.5 ULN
3)Serum creatinine <= 1.5 ULN or calculated creatinine clearance >= 50 mL/min according to Cockcroft formula (or to MDRD formula for patients older than 65 years-old).
7.Adequate coagulation panel:
1)PT <=1.2 ULN
2)aPTT <= 1.5 ULN
3)INR <= 1.5 ULN
8.Adequate neurologic function: only neuropathy (sensory and motor) grade <= 1 (CTCAE v4.3) are allowed
9.ECOG Performance status of 0, 1, or 2
10.Life expectancy >= 4 months
11.Satisfactory cardiac function
12.Ability to understand and sign informed consent and willingness to comply with the study procedures before study entry
13.Women of childbearing potential are required to have a negative serum pregnancy test within 7 days prior to study treatment initiation (i.e. Cycle 1 Day 1) and are willing to use adequate contraceptive method during the whole study period and for up to 6 months after the last treatment intake
14.Covered by a medical insurance (in country where applicable)
Key exclusion criteria
1.Prior systemic therapy with bevacizumab
2.Active peripheral neuropathy >= grade 3 (NCI-CTCAE v4.3)
3.Prior history of other malignancies other than ovarian SCST unless the subjects has been free of the disease for at least 3 years or 5 years for breast cancer
4.No resolution of specific toxicities related to any prior anti-cancer therapy to grade <=1, excluding alopecia, according to the NCI-CTCAE v.4.3
5.History or evidence of thrombotic or hemorrhagic disorders or transient ischemic attack or sub-arachnoids' haemorrhage within 6 months prior to first dose of study drugs
6.Uncontrolled arterial hypertension despite optimal antihypertensive therapy or clinically significant cardiovascular disease
7.History of bowel obstruction, including sub-occlusive syndrome and history of abdominal fistula, gastro-intestinal perforation or intra-abdominal abscess during the year prior to inclusion
8.Prior treatments:
1)Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study
2)Another investigational drug within 30 days of first study treatment dosing
3)Chronic use of aspirin> 325 mg/day or use of any other inhibitor of platelet aggregation
4)Chronic treatment with non steroids anti-inflammatory agents
5)Intake of granulocyte growth factor within 3 weeks before study entry
9.Treatment during the study:
1)Debulking surgery prior to disease progression is not foreseen
2)Concurrent radiotherapy during the study treatment
10.Presence of hematuria and proteinuria >= 2+ (urine dipstick).
11.Untreated evolutive brain metastases
12.Active bacteria or fungal infection 13.Known HIV1, HIV2 or chronic hepatitis B or C infection
14.Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
15.Any contraindications to paclitaxel treatment: for example severe hypersensitivity reactions to paclitaxel or to any of the excipients
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Isabelle RAY-COQUARD |
Organization
Centre Leon Berard, LYON, FRANCE
Division name
-
Zip code
Address
Lyon, France, 69373
TEL
+33-4-78-78-28-28
isabelle.ray-coquard@lyon.unicancer.fr
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Keiichi Fujiwara, MD.,PhD |
Organization
Saitama Medical University International Medical Center
Division name
Department of Gynecologic Oncology
Zip code
Address
1397-1 Yamane, Hidaka-city, Saitama
TEL
+81-42-984-4111
Homepage URL
fujiwara@saitama-med.ac.jp
Sponsor or person
Institute
ARCAGY/ GINECO GROUP
Institute
Department
Personal name
Funding Source
Organization
GOTIC (Gynecologic Oncology Trial and Investigation Consortium of Kanto)
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
YES
Study ID_1
NCT01770301
Org. issuing International ID_1
ClinicalTrials.gov
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
埼玉医科大学国際医療センター（埼玉県）
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 01 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 09 | Month | 06 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 01 | Month | 07 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 01 | Month | 06 | Day |
Last modified on
| 2019 | Year | 02 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018738
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
